首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1975196

全球雙特異性抗體市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Bispecific Antibody Market Size, Share, Trends & Growth Analysis Report 2026-2034

出版日期: 2026年02月05日 | 出版商:

Value Market Research | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

雙特異性抗體市場預計將從 2025 年的 117.3 億美元成長到 2034 年的 293.5 億美元，2026 年至 2034 年的複合年成長率為 10.73%。

受免疫療法和腫瘤學研究進展的推動，全球雙特異性抗體市場正經歷快速擴張。雙特異性抗體能夠同時結合兩種不同的抗原，從而提供更具標靶性和更有效的治療方案，尤其是在癌症治療領域。癌症發生率的上升和對精準醫療需求的日益成長是推動市場成長的關鍵因素。

對生物技術研發和臨床試驗的大量投資正在加速新型雙特異性抗體候選藥物的開發。製藥公司正與研究機構合作，以提高療效並減少副作用。創新生物製藥獲得監管部門核准，進一步增強了市場信心，並拓寬了患者的治療選擇。

隨著研發線產品順利推動臨床試驗，未來前景十分光明。除癌症治療外，雙特異性抗體在自體免疫疾病和感染疾病等領域的應用也在探索之中。隨著產能的擴大和抗體工程技術的進步，預計未來幾年雙特異性抗體市場將實現顯著成長。

區域分析
北美市場分析、洞察與預測
- 美國
- 加拿大
- 墨西哥
歐洲市場分析、洞察與預測
- 英國
- 法國
- 德國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太市場分析、洞察與預測
- 印度
- 日本
- 韓國
- 澳洲
- 東南亞
- 亞太其他地區
拉丁美洲市場分析、洞察與預測
- 巴西
- 阿根廷
- 秘魯
- 智利
- 其他拉丁美洲國家
中東和非洲市場分析、洞察與預測
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 其他中東和非洲國家

第9章競爭情勢

最新趨勢
公司分類
供應鏈和銷售管道合作夥伴（根據現有資訊）
市場佔有率和市場定位分析（基於現有資訊）
供應商情況（基於現有資訊）
策略規劃

第10章：公司簡介

主要公司的市佔率分析
公司簡介
- Pfizer
- Takeda Pharmaceutical
- Roche
- AbbVie
- Eli Lilly
- Bristol Myers Squibb
- GSK
- Genmab
- Novartis
- Regeneron Pharmaceuticals
- Astellas Pharma
- Merck
- Xencor
- Amgen
- Sanofi

簡介目錄

Product Code: VMR112112047

The Bispecific Antibody Market size is expected to reach USD 29.35 Billion in 2034 from USD 11.73 Billion (2025) growing at a CAGR of 10.73% during 2026-2034.

The global bispecific antibody market is witnessing rapid expansion driven by advancements in immunotherapy and oncology research. Bispecific antibodies are designed to bind two different antigens simultaneously, offering targeted and more effective treatment options, particularly in cancer therapy. Rising cancer prevalence and increasing demand for precision medicine are major contributors to market growth.

Significant investments in biotechnology research and clinical trials have accelerated the development of novel bispecific antibody candidates. Pharmaceutical companies are collaborating with research institutions to enhance therapeutic efficacy and reduce side effects. Regulatory approvals of innovative biologics have further strengthened market confidence and expanded treatment options for patients.

Future prospects remain highly positive as pipeline products continue to advance through clinical stages. Applications beyond oncology, including autoimmune and infectious diseases, are being explored. With expanding manufacturing capabilities and technological progress in antibody engineering, the bispecific antibody market is expected to achieve substantial growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

Cancer Treatment
Autoimmune Disorders
Infectious Diseases
Transplant Rejection

By Type

IgG-based Bispecific Antibodies
ScFv-based Bispecific Antibodies
Bispecific T-cell Engager Antibodies

By Mechanism of Action

Direct Cell-killing
Immune Modulation
Cytokine Release

By End-Use

Pharmaceutical Companies
Research Institutions
Clinical Research Organizations

COMPANIES PROFILED

Pfizer, Takeda Pharmaceutical, Roche, AbbVie, Eli Lilly, Bristol Myers Squibb, GSK, Genmab, Novartis, Regeneron Pharmaceuticals, Astellas Pharma, Merck, Xencor, Amgen, Sanofi
We can customise the report as per your requirements.

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL BISPECIFIC ANTIBODY MARKET: BY APPLICATION 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Application
4.2. Cancer Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Autoimmune Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Transplant Rejection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BISPECIFIC ANTIBODY MARKET: BY TYPE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Type
5.2. IgG-based Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. ScFv-based Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Bispecific T-cell Engager Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BISPECIFIC ANTIBODY MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Mechanism Of Action
6.2. Direct Cell-killing Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Immune Modulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Cytokine Release Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BISPECIFIC ANTIBODY MARKET: BY END-USE 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast End-use
7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Clinical Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BISPECIFIC ANTIBODY MARKET: BY REGION 2022-2034(USD MN)

8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Application
- 8.2.2 By Type
- 8.2.3 By Mechanism Of Action
- 8.2.4 By End-use
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Application
- 8.3.2 By Type
- 8.3.3 By Mechanism Of Action
- 8.3.4 By End-use
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Application
- 8.4.2 By Type
- 8.4.3 By Mechanism Of Action
- 8.4.4 By End-use
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Application
- 8.5.2 By Type
- 8.5.3 By Mechanism Of Action
- 8.5.4 By End-use
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Application
- 8.6.2 By Type
- 8.6.3 By Mechanism Of Action
- 8.6.4 By End-use
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BISPECIFIC ANTIBODY INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Company Profiles
- 10.2.1 Pfizer
- 10.2.2 Takeda Pharmaceutical
- 10.2.3 Roche
- 10.2.4 AbbVie
- 10.2.5 Eli Lilly
- 10.2.6 Bristol Myers Squibb
- 10.2.7 GSK
- 10.2.8 Genmab
- 10.2.9 Novartis
- 10.2.10 Regeneron Pharmaceuticals
- 10.2.11 Astellas Pharma
- 10.2.12 Merck
- 10.2.13 Xencor
- 10.2.14 Amgen
- 10.2.15 Sanofi